Russell Investments Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Russell Investments Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Buy	12,391 +8,965	+262%	+$163K	﹤0.01%	3106
2026 Q1	$63.9K	Hold	3,426	–	–	﹤0.01%	3231
2025 Q4	$45.2K	Buy	3,426 +1,069	+45%	+$12.6K	﹤0.01%	3339
2025 Q3	$16.9K	Sell	2,357 -3,103	-57%	-$162K	﹤0.01%	3638
2025 Q2	$258K	Hold	5,460	–	–	﹤0.01%	2576
2025 Q1	$213K	Sell	5,460 -50,430	-90%	-$2.17M	﹤0.01%	2571
2024 Q4	$3.03M	Sell	55,890 -6,140	-10%	-$314K	﹤0.01%	1436
2024 Q3	$3.13M	Buy	62,030 +28,471	+85%	+$1.33M	﹤0.01%	1449
2024 Q2	$1.48M	Buy	+33,559	New	+$1.42M	﹤0.01%	1789

Other funds holding MLTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group's MLTX Position: Q2 2026 in Review

Russell Investments Group increased its MoonLake Immunotherapeutics (MLTX) stake by 262% in Q2 2026, buying an estimated $163K and bringing the position to 12,391 shares worth $241K. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

Russell Investments Group first reported a position in MLTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.13M in Q3 2024. 51 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Russell Investments Group held 12,391 shares of MoonLake Immunotherapeutics worth $241K as of Q2 2026.
Russell Investments Group bought 8,965 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $163K.
MoonLake Immunotherapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #3106 holding.
Russell Investments Group first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 9 quarters since.
Russell Investments Group's MoonLake Immunotherapeutics position peaked at $3.13M in Q3 2024.
51 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.